209 related articles for article (PubMed ID: 36271030)
1. A novel network pharmacology approach for leukaemia differentiation therapy using Mogrify
Lee LM; Christodoulou EG; Shyamsunder P; Chen BJ; Lee KL; Fung TK; So CWE; Wong GC; Petretto E; Rackham OJL; Tiong Ong S
Oncogene; 2022 Nov; 41(48):5160-5175. PubMed ID: 36271030
[TBL] [Abstract][Full Text] [Related]
2. Transcription therapy for acute promyelocytic leukaemia.
Douer D
Expert Opin Investig Drugs; 2000 Feb; 9(2):329-46. PubMed ID: 11060680
[TBL] [Abstract][Full Text] [Related]
3. All-trans retinoic acid (ATRA)-induced TFEB expression is required for myeloid differentiation in acute promyelocytic leukemia (APL).
Orfali N; O'Donovan TR; Cahill MR; Benjamin D; Nanus DM; McKenna SL; Gudas LJ; Mongan NP
Eur J Haematol; 2020 Mar; 104(3):236-250. PubMed ID: 31811682
[TBL] [Abstract][Full Text] [Related]
4. [Effects of interferon regulatory factor 9 on the biological phenotypes in PML-RARα-induced promyelocytic leukemia].
Yang X; Xing HY; Tang KJ; Tian Z; Rao Q; Wang M; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2022 May; 43(5):370-375. PubMed ID: 35680593
[No Abstract] [Full Text] [Related]
5. Targeting of PML/RARalpha is lethal to retinoic acid-resistant promyelocytic leukemia cells.
Nason-Burchenal K; Allopenna J; Bègue A; Stéhelin D; Dmitrovsky E; Martin P
Blood; 1998 Sep; 92(5):1758-67. PubMed ID: 9716606
[TBL] [Abstract][Full Text] [Related]
6. Activation of
Zhang F; Zhu YL; Deng WL; Zhu J; Zhang J
J Leukoc Biol; 2017 Mar; 101(3):655-664. PubMed ID: 27605212
[TBL] [Abstract][Full Text] [Related]
7. Expression of the Zn finger gene, EVI-1, in acute promyelocytic leukemia.
Xi ZF; Russell M; Woodward S; Thompson F; Wagner L; Taetle R
Leukemia; 1997 Feb; 11(2):212-20. PubMed ID: 9009083
[TBL] [Abstract][Full Text] [Related]
8. The PML-RARalpha fusion protein and targeted therapy for acute promyelocytic leukemia.
Jing Y
Leuk Lymphoma; 2004 Apr; 45(4):639-48. PubMed ID: 15160934
[TBL] [Abstract][Full Text] [Related]
9. PML-RARα interferes with erythropoiesis by repressing LMO2 in acute promyelocytic leukaemia.
Yang X; Tan Y; Wang P; Zhang H; Zhao M; Zhao X; Wang K
J Cell Mol Med; 2018 Dec; 22(12):6275-6284. PubMed ID: 30320491
[TBL] [Abstract][Full Text] [Related]
10. Autophagy and Ubiquitin-Mediated Proteolytic Degradation of PML/Rarα Fusion Protein in Matrine-Induced Differentiation Sensitivity Recovery of ATRA-Resistant APL (NB4-LR1) Cells: in Vitro and in Vivo Studies.
Wu D; Shao K; Zhou Q; Sun J; Wang Z; Yan F; Liu T; Wu X; Ye B; Huang H; Zhou Y
Cell Physiol Biochem; 2018; 48(6):2286-2301. PubMed ID: 30114705
[TBL] [Abstract][Full Text] [Related]
11. Selenite promotes all-trans retinoic acid-induced maturation of acute promyelocytic leukemia cells.
Misra S; Selvam AK; Wallenberg M; Ambati A; Matolcsy A; Magalhaes I; Lauter G; Björnstedt M
Oncotarget; 2016 Nov; 7(46):74686-74700. PubMed ID: 27732960
[TBL] [Abstract][Full Text] [Related]
12. Identification of B94 (TNFAIP2) as a potential retinoic acid target gene in acute promyelocytic leukemia.
Rusiniak ME; Yu M; Ross DT; Tolhurst EC; Slack JL
Cancer Res; 2000 Apr; 60(7):1824-9. PubMed ID: 10766166
[TBL] [Abstract][Full Text] [Related]
13. Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML- and PLZF-RARalpha underlie molecular pathogenesis and treatment of acute promyelocytic leukemia.
Guidez F; Ivins S; Zhu J; Söderström M; Waxman S; Zelent A
Blood; 1998 Apr; 91(8):2634-42. PubMed ID: 9531570
[TBL] [Abstract][Full Text] [Related]
14. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy.
Zhou GB; Zhang J; Wang ZY; Chen SJ; Chen Z
Philos Trans R Soc Lond B Biol Sci; 2007 Jun; 362(1482):959-71. PubMed ID: 17317642
[TBL] [Abstract][Full Text] [Related]
15. Understanding the molecular pathogenesis of acute promyelocytic leukemia.
Lo-Coco F; Hasan SK
Best Pract Res Clin Haematol; 2014 Mar; 27(1):3-9. PubMed ID: 24907012
[TBL] [Abstract][Full Text] [Related]
16. Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells.
Albanesi J; Noguera NI; Banella C; Colangelo T; De Marinis E; Leone S; Palumbo O; Voso MT; Ascenzi P; Nervi C; Bianchi F; di Masi A
Cells; 2020 Nov; 9(11):. PubMed ID: 33167477
[TBL] [Abstract][Full Text] [Related]
17. Skp2 promotes APL progression through the stabilization of oncoprotein PML-RARα and the inhibition of JunB expression.
Dan W; Zhong L; Yu L; Xiong L; Li J; Ye J; Luo X; Liu C; Chu X; Liu B
Life Sci; 2022 Jan; 289():120231. PubMed ID: 34921867
[TBL] [Abstract][Full Text] [Related]
18. PML/RARα-Regulated miR-181a/b Cluster Targets the Tumor Suppressor RASSF1A in Acute Promyelocytic Leukemia.
Bräuer-Hartmann D; Hartmann JU; Wurm AA; Gerloff D; Katzerke C; Verga Falzacappa MV; Pelicci PG; Müller-Tidow C; Tenen DG; Niederwieser D; Behre G
Cancer Res; 2015 Aug; 75(16):3411-24. PubMed ID: 26041820
[TBL] [Abstract][Full Text] [Related]
19. The clinically relevant CHK1 inhibitor MK-8776 induces the degradation of the oncogenic protein PML-RARα and overcomes ATRA resistance in acute promyelocytic leukemia cells.
Franza M; Albanesi J; Mancini B; Pennisi R; Leone S; Acconcia F; Bianchi F; di Masi A
Biochem Pharmacol; 2023 Aug; 214():115675. PubMed ID: 37406967
[TBL] [Abstract][Full Text] [Related]
20. Hypoxia-simulating agents and selective stimulation of arsenic trioxide-induced growth arrest and cell differentiation in acute promyelocytic leukemic cells.
Yan H; Peng ZG; Wu YL; Jiang Y; Yu Y; Huang Y; Zhu YS; Zhao Q; Chen GQ
Haematologica; 2005 Dec; 90(12):1607-16. PubMed ID: 16330433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
